| Item Type | Name |
|
Concept
|
Double-Blind Method
|
|
Academic Article
|
Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy.
|
|
Academic Article
|
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
|
|
Academic Article
|
Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study.
|
|
Academic Article
|
A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes.
|
|
Academic Article
|
Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?
|
|
Academic Article
|
Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring.
|
|
Academic Article
|
Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches.
|
|
Academic Article
|
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
|
|
Academic Article
|
Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study.
|
|
Academic Article
|
Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes.
|
|
Academic Article
|
Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria.
|
|
Academic Article
|
Exceptional early blood pressure control rates: the ACCOMPLISH trial.
|
|
Academic Article
|
Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes.
|
|
Academic Article
|
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial.
|
|
Academic Article
|
beta-blocker use and diabetes symptom score: results from the GEMINI study.
|
|
Academic Article
|
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.
|
|
Academic Article
|
The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy.
|
|
Academic Article
|
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
|
|
Academic Article
|
Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study.
|
|
Academic Article
|
Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study.
|
|
Academic Article
|
The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial.
|
|
Academic Article
|
Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients.
|
|
Academic Article
|
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.
|
|
Academic Article
|
The effect of ruboxistaurin on nephropathy in type 2 diabetes.
|
|
Academic Article
|
Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients.
|
|
Academic Article
|
Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension.
|
|
Academic Article
|
Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes.
|
|
Academic Article
|
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
|
|
Academic Article
|
Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies.
|
|
Academic Article
|
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
|
|
Academic Article
|
Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study.
|
|
Academic Article
|
Importance of blood pressure control in left ventricular mass regression.
|
|
Academic Article
|
Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy.
|
|
Academic Article
|
Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.
|
|
Academic Article
|
Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial.
|
|
Academic Article
|
Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial.
|
|
Academic Article
|
Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study.
|
|
Academic Article
|
The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
|
|
Academic Article
|
Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study.
|
|
Academic Article
|
Renal effects of oral prostaglandin supplementation after ibuprofen in diabetic subjects: a double-blind, placebo-controlled, multicenter trial.
|
|
Academic Article
|
Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.
|
|
Academic Article
|
Body weight changes with beta-blocker use: results from GEMINI.
|
|
Academic Article
|
Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
|
|
Academic Article
|
Renal outcomes in hypertensive Black patients at high cardiovascular risk.
|
|
Academic Article
|
Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy.
|
|
Academic Article
|
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
|
|
Academic Article
|
Atlas vertebra realignment and achievement of arterial pressure goal in hypertensive patients: a pilot study.
|
|
Academic Article
|
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study.
|
|
Academic Article
|
The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.
|
|
Academic Article
|
Effects of naproxcinod on blood pressure in patients with osteoarthritis.
|
|
Academic Article
|
Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.
|
|
Academic Article
|
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
|
|
Academic Article
|
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial.
|
|
Academic Article
|
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
|
|
Academic Article
|
Systolic blood pressure and cardiovascular outcomes during treatment of hypertension.
|
|
Academic Article
|
Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease.
|
|
Academic Article
|
Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril.
|
|
Academic Article
|
Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus.
|
|
Academic Article
|
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
|
|
Academic Article
|
Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
|
|
Academic Article
|
Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3.
|
|
Academic Article
|
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
|
|
Academic Article
|
Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial.
|
|
Academic Article
|
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
|
|
Academic Article
|
Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy.
|
|
Academic Article
|
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.
|
|
Academic Article
|
Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension.
|
|
Academic Article
|
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
|
|
Academic Article
|
Efficacy and safety of perindopril arginine + amlodipine in hypertension.
|
|
Academic Article
|
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
|
|
Academic Article
|
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
|
|
Academic Article
|
Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension.
|
|
Academic Article
|
Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS.
|
|
Academic Article
|
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
|
|
Academic Article
|
Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy.
|
|
Academic Article
|
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
|
|
Academic Article
|
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
|
|
Academic Article
|
Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
|
|
Academic Article
|
Relationship Between Obesity, Hypertension, and Aldosterone Production in Postmenopausal African American Women: A Pilot Study.
|
|
Academic Article
|
Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).
|
|
Academic Article
|
Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up.
|
|
Academic Article
|
Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension.
|
|
Academic Article
|
Baseline characteristics and enrichment results from the SONAR trial.
|
|
Academic Article
|
A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension.
|
|
Academic Article
|
Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment.
|
|
Academic Article
|
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
|
|
Academic Article
|
High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.
|
|
Academic Article
|
Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.
|
|
Academic Article
|
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.
|
|
Academic Article
|
Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial.
|
|
Academic Article
|
Initial Single-Pill Blood Pressure-Lowering Therapy: Should It Be for Most People?
|
|
Academic Article
|
Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.
|
|
Academic Article
|
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
|
|
Academic Article
|
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
|
|
Academic Article
|
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
|
|
Academic Article
|
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
|
|
Academic Article
|
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
|
|
Academic Article
|
Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial.
|
|
Academic Article
|
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
|
|
Academic Article
|
Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial.
|
|
Academic Article
|
Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes?
|
|
Academic Article
|
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.
|
|
Academic Article
|
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
|
|
Academic Article
|
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.
|
|
Academic Article
|
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial.
|
|
Academic Article
|
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
|
|
Academic Article
|
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
|
|
Academic Article
|
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease.
|
|
Academic Article
|
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
|
|
Academic Article
|
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
|
|
Academic Article
|
Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome.
|
|
Academic Article
|
Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study.
|
|
Academic Article
|
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
|
|
Academic Article
|
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.
|
|
Academic Article
|
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial.
|
|
Academic Article
|
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
|
|
Academic Article
|
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
|
|
Academic Article
|
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.
|
|
Academic Article
|
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
|
|
Academic Article
|
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.
|
|
Academic Article
|
Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.
|
|
Academic Article
|
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.
|
|
Academic Article
|
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease.
|
|
Academic Article
|
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline.
|
|
Academic Article
|
Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.
|
|
Academic Article
|
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis.
|
|
Academic Article
|
RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial.
|
|
Academic Article
|
Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials.
|